• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / Onalespib (AT13387) – HSP90 inhibitor2 / 20093 / 2009 EORTC: Fragment Based Drug Discovery of HSP90 Inhibitor AT13387

2009 EORTC: Fragment Based Drug Discovery of HSP90 Inhibitor AT13387

25 November 2009/in 2009, Onalespib (AT13387) – HSP90 inhibitor, Products

2009 EORTC: Fragment Based Drug Discovery of HSP90 Inhibitor AT13387

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2009-11-25 15:29:512016-11-25 15:30:242009 EORTC: Fragment Based Drug Discovery of HSP90 Inhibitor AT13387

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: 2009 AACR: ID of Predicted Biologically Effective Dose of AT7519 in Phase 1 Study Link to: 2009 AACR: ID of Predicted Biologically Effective Dose of AT7519 in Phase 1 Study 2009 AACR: ID of Predicted Biologically Effective Dose of AT7519 in Phase 1... Link to: Howard et al. “Fragment-Based Discovery of the Pyrazol-4-yl urea (AT9283), a Multi-targeted Kinase Inhibitor with Potent Aurora Kinase Activity.” Journal of Medicinal Chemistry 52, no. 2 2009: 379–388. DOI: 10.1021/jm800984v. Link to: Howard et al. “Fragment-Based Discovery of the Pyrazol-4-yl urea (AT9283), a Multi-targeted Kinase Inhibitor with Potent Aurora Kinase Activity.” Journal of Medicinal Chemistry 52, no. 2 2009: 379–388. DOI: 10.1021/jm800984v. Howard et al. “Fragment-Based Discovery of the Pyrazol-4-yl urea (AT9283),...
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok